XML 37 R25.htm IDEA: XBRL DOCUMENT
v3.19.2

Acquisitions - Additional Information (Detail) - USD ($) |  |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
May 16, 2018 | Jul. 19, 2017 | Jun. 30, 2019 | Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018
Business Combination Reverse Merger [Line Items] |  |  |  |  |  |  |
Cash and cash equivalents |  | $ 9,900,000 |  |  |  |  |
Unamortized fair value of stock options |  | $ 3,700,000 |  |  |  |  |
Goodwill impairment charge |  |  | $ 0 | $ 0 | $ 5,200,000 | $ 0 | $ 5,187,519
Pear Tree Pharmaceuticals, Inc. |  |  |  |  |  |  |
Business Combination Reverse Merger [Line Items] |  |  |  |  |  |  |
Potential cash payments to acquire business | $ 75,000 |  |  |  |  |  |
Consideration amount | 132,000 |  |  |  |  |  |
Research and Development Expense | Pear Tree Pharmaceuticals, Inc. |  |  |  |  |  |  |
Business Combination Reverse Merger [Line Items] |  |  |  |  |  |  |
Transaction costs | $ 452,000 |  |  |  |  |  |

X
- Definition Business combination reverse merger. + References No definition available. + Details
Name: | dare_BusinessCombinationReverseMergerLineItems
Namespace Prefix: | dare_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. + References No definition available. + Details
Name: | dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business combination reverses merger stock purchase transaction cost. + References No definition available. + Details
Name: | dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business combination reverse merger unamortized fair value of stock options. + References No definition available. + Details
Name: | dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Cash Payments To Acquire Business + References No definition available. + Details
Name: | dare_PotentialCashPaymentsToAcquireBusiness
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |